Mesothelioma Patients Experienced Higher Levels of Toxicity on CheckMate743 Regimen Than Reported in Clinical Trials
Erin JungmeyerDr. Ned McNamee said the RIOMeso study is the first detailed report of real-world outcomes in Australian patients undergoing ipi + nivo treatment for pleural meso. Read more
Proposed Criteria for Tumor Invasion Align with Clinical Factors, Offer Better Predictability, Study Finds
Erin JungmeyerResearchers evaluating the clinical significance of IASLC-proposed criteria found the recommendations better align with clinicopathologic risk factors and improve prognostication. Read more
Patient Perspective: Patients With EGFR+ NSCLC May Still Opt for Quality Over Quantity After FLAURA2
Ivy Elkins, MBAIn light of recent data from the study of osimertinib with or without chemotherapy, patient advocate Ivy Elkins said the results may sway some to add chemo to their first-line treatment plan. However, for others, the impact on quality of life will not be worth it. Read more
Transporting Real-World Evidence Between Countries—Ready to Beam Aboard?
Jamie Feng, MD+more
When novel agents demonstrate high rates of durable treatment response but comparative outcome data with standard treatments are lacking, it is important to have methods to translate those treatments to different settings. Read more
Neoadjuvant Immunotherapy in NSCLC: A Window of Opportunity Not to Be Missed
Jamie E. Chaft, MDDr. Jamie Chaft says neoadjuvant chemoimmunotherapy offers thoracic oncologists an opportunity to cure more patients. Read more
Adjuvant IO for Operable NSCLC: Where Does It Fit a Changing Landscape?
Michael Davidson, MD+more
Dr. Mary O’Brien and colleagues say decision making around operable cases is becoming increasingly complex, making a multidisciplinary approach imperative. Read more
Demystifying AI: How Will Artificial Intelligence Alter the Practice of Thoracic Oncology?
Raymond H. Mak, MD+more
In Part 2 of their exploration of artificial intelligence, Dr. Raymond Mak and Fridolin Haugg reflect on the possibilities ahead for the diagnosis and treatment of lung cancer. Read more
Inflammation’s Dark Symphony: Lung Cancer and Depression in Concert
Barbara L. Andersen, PhDDr. Barbara Andersen’s research has shown depression severity is associated with prognostically poor inflammation in patients with non-small cell lung cancer. Read more
Demystifying AI: Current Insights on Artificial Intelligence in Thoracic Oncology
Raymond H. Mak, MD+more
Dr. Raymond Mak and Fridolin Haugg delve into the artificial intelligence discussion with an overview of AI basics and a look at how AI is already influencing the lung cancer field. Read more
Artificial Intelligence in Healthcare: A Patient Perspective
Angus Pratt, MBAWhen life-and-death decisions are at stake, will patients welcome AI to their care team? As part of ILCN’s series on AI in lung cancer, patient advocate Angus Pratt explores issues of trust, safety, accuracy, and more. Read more